No Data
Co-Rays Diagnostics (688468.SH): Hengqin Junlian Zhi Kang and its concerted parties have cumulatively reduced their shareholding by 1.99%.
Gelonghui, November 6th - Kemei Diagnostics (688468.SH) announced that on November 5, 2024, the company received a brief equity changes report from the company's shareholder Hengqin Junlian ZhiKang and its concerted action person LOYALCLASS. During the period from August 15, 2024 to November 5, 2024. Hengqin Junlian ZhiKang and its concerted action person LOYALCLASS collectively reduced their shareholding in the company by 7,975,214 shares, accounting for 1.99% of the total share capital of the company. After this equity change, Hengqin Junlian ZhiKang and its
Komei Diagnostic Technology Co., Ltd. Third Quarter Report 2024
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
Komei Diagnostic Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Komei Diagnostic Technology Co., Ltd.
Kemei Diagnosis (688468.SH): has repurchased 1.62% of the company's shares.
As of July 31st, 2024, Kemei Diagnostic (688468.SH) announced that it has repurchased a total of 6.5149 million shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 1.62% of the total share capital of 401,108,000 shares. The highest and lowest transaction prices for the buyback were 10.30 yuan/share and 5.83 yuan/share, respectively. The company has paid a total of 51.0751 million yuan (excluding stamp duty, trading commission and other transaction costs).
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Business And Shares Still Trailing The Market
